No Increased Risk for One-and-Done Breast Reconstruction

Share this content:
No Increased Risk for One-and-Done Breast Reconstruction
No Increased Risk for One-and-Done Breast Reconstruction

WEDNESDAY, Aug. 5, 2015 (HealthDay News) -- Single-stage implant breast reconstruction is a less invasive procedure that may offer good aesthetic outcome with no additional oncologic risk in selected patients, according to research published in the August issue of Plastic and Reconstructive Surgery.

Jose Rodriguez-Feliz, M.D., of Emory University, and Mark A. Codner, M.D., of Mark Codner Plastic Surgery -- both in Atlanta, describe surgical experience for 27 single-stage breast implant reconstructions performed by Codner. The authors also conducted a literature review to further examine patient selection, implant selection, and mastectomy incision choices.

The researchers found that, for the 27 single-stage breast implant reconstructions, the average mastectomy weight was 343.82 g, and the average implant volume was 367 cc. For implant selection, shaped implants were the most common choice. In all breast reconstructions, acellular dermal matrix was used. Complications included erythema requiring intravenous antibiotic therapy, in three patients; exposed/infected implants (salvaged using a published sequential irrigation protocol), in two patients; and skin ischemia caused by methylene blue, seroma, unilateral partial nipple necrosis, and mastectomy skin necrosis, each in one patient.

"Selected patients will benefit from a one-and-done breast implant reconstruction with no additional oncologic risk," the authors write. "Surgeons must embrace the change and provide their patients with a procedure that will offer the best aesthetic outcomes."

One author disclosed financial ties to biomedical and medical publishing companies.

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »